Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116389 · ClinicalTrials.gov registry record · Phase 2
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by Point Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00116389: Clinical Trial Phase 2 study, sponsored by Point Therapeutics.
NCT00116389 is a Phase 2 study that was terminated before completion, run by Point Therapeutics. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116389, a Phase 2 study, was terminated before completion, sponsored by Point Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
Interventions
- DRUG gemcitabine
- DRUG talabostat mesylate tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
Why NCT00116389 stopped before completion
NCT00116389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00116389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116389 about?
NCT00116389 is a clinical study titled "Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas". The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
What is the current status of trial NCT00116389?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00116389?
The interventions under investigation include: gemcitabine (DRUG), talabostat mesylate tablets (DRUG).
Who is sponsoring clinical trial NCT00116389?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116389's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors